[{"NetIncomeLoss_1_Q2_USD":-8481000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":16268000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":8603000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":16182000.0,"InventoryFinishedGoods_0_Q2_USD":328000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":1764000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":26106000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-287000.0,"AssetsCurrent_0_Q2_USD":216523000.0,"DerivativeGainLossOnDerivativeNet_2_Q2_USD":38412000.0,"DerivativeGainLossOnDerivativeNet_1_Q2_USD":13396000.0,"Liabilities_0_Q2_USD":150460000.0,"DilutiveSecurities_2_Q2_USD":-38412000.0,"DebtInstrumentUnamortizedDiscount_0_Q2_USD":124000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":1988000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":1096000.0,"SellingAndMarketingExpense_2_Q2_USD":16477000.0,"SellingAndMarketingExpense_1_Q2_USD":8391000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0_Q2_shares":11049287.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":538000.0,"ConvertibleDebtNoncurrent_0_Q2_USD":25348000.0,"UnrecognizedTaxBenefits_0_Q2_USD":0.0,"CommonStockSharesIssued_0_Q2_shares":76454597.0,"Assets_0_Q2_USD":230707000.0,"ShareBasedCompensation_2_Q2_USD":7378000.0,"DilutiveSecurities_1_Q2_USD":-13396000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":5378000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":624850000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":191860000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":1077000.0,"IncomeTaxExaminationPenaltiesAndInterestAccrued_0_Q2_USD":0.0,"ResearchAndDevelopmentExpense_2_Q2_USD":24786000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":13859000.0,"InventoryRawMaterials_0_Q2_USD":347000.0,"EarningsPerShareBasic_2_Q2_USD":-0.07,"EarningsPerShareBasic_1_Q2_USD":-0.11,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":81967616.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":82093599.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":928000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":1000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":1000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":6770000.0,"AccountsReceivableNetCurrent_0_Q2_USD":18734000.0,"LongTermNotesPayable_0_Q2_USD":24891000.0,"InvestmentIncomeNet_2_Q2_USD":20000.0,"InvestmentIncomeNet_1_Q2_USD":8000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":1257000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":1505000.0,"CostsAndExpenses_2_Q2_USD":59519000.0,"CostsAndExpenses_1_Q2_USD":31949000.0,"ProceedsFromNotesPayable_2_Q2_USD":3722000.0,"IncreaseDecreaseInInventories_2_Q2_USD":-89000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-5360000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-8481000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":1255000.0,"CommonStockValue_0_Q2_USD":8000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":-275000.0,"RepaymentsOfNotesPayable_2_Q2_USD":4167000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":4292000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-37415000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":76198384.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":76324367.0,"InventoryWorkInProcess_0_Q2_USD":437000.0,"IncrementalCommonSharesAttributableToConversionOfDebtSecurities_2_Q2_shares":5769232.0,"IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1_Q2_shares":5769232.0,"LiabilitiesCurrent_0_Q2_USD":21550000.0,"AccountsPayableCurrent_0_Q2_USD":3881000.0,"NonoperatingIncomeExpense_2_Q2_USD":35098000.0,"NonoperatingIncomeExpense_1_Q2_USD":11750000.0,"InterestExpense_2_Q2_USD":3335000.0,"AmortizationOfFinancingCosts_2_Q2_USD":2282000.0,"InterestExpense_1_Q2_USD":1655000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2_Q2_USD":490000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":4817000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":1735000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":913000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_2_Q2_USD":-41599000.0,"NetIncomeLossAvailableToCommonStockholdersDiluted_1_Q2_USD":-20782000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":490000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"LineOfCreditFacilityMaximumBorrowingCapacity_0_Q2_USD":25000000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":8000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":7042000.0,"NetIncomeLoss_2_Q2_USD":-5360000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":193624000.0,"IncreaseDecreaseInDerivativeLiabilities_2_Q2_USD":38412000.0,"EarningsPerShareDiluted_1_Q2_USD":-0.25,"EarningsPerShareDiluted_2_Q2_USD":-0.51,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"NotesPayable_0_Q2_USD":24891000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":167000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":19061000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":11718000.0,"OperatingIncomeLoss_2_Q2_USD":-40458000.0,"OperatingIncomeLoss_1_Q2_USD":-20231000.0,"InventoryNet_0_Q2_USD":1112000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":230707000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":4873000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"DerivativeLiabilities_0_Q2_USD":59901000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":7378000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":4292000.0,"DerivativeLiabilitiesNoncurrent_0_Q2_USD":59901000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1487000.0,"ProfitLoss_2_Q2_USD":-5360000.0,"StockholdersEquity_0_Q2_USD":80247000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":12000000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":287000.0,"DebtInstrumentCarryingAmount_0_Q2_USD":25000000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-544611000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-36197000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":6482000.0,"CommonStockSharesOutstanding_0_Q2_shares":76454597.0,"InterestOnConvertibleDebtNetOfTax_1_Q2_USD":1095000.0,"InterestOnConvertibleDebtNetOfTax_2_Q2_USD":2173000.0,"Ticker":"OCUL","CIK":"1393434","name":"OCULAR THERAPEUTIX, INC","OfficialName":"Ocular Therapeutix Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"305481557.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210809"}]